Suppression of Cytokine Release Syndrome During CAR-T-Cell Therapy via a Subcutaneously Injected Interleukin-6-Adsorbing Hydrogel

Researchers showed that a temperature-sensitive hydrogel conjugated with antibodies for the pro-inflammatory cytokine interleukin-6 and subcutaneously injected before the infusion of CAR-T cells substantially reduced the levels of IL-6 during cytokine release syndrome while maintaining the therapy’s antitumor efficacy.